Clinical Trial Update: An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) [Phase 3]

View source ↗

Summary

A phase 3 trial comparing trabectedin to doxorubicin-based chemotherapy in translocation-related sarcomas has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma
• Translocation-related Sarcoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• Trabectedin (trabectedin)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Sarcoma | Phase 3 | Status: COMPLETED | Results posted: 2014-09-16